Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:09PM ET
40.16
Dollar change
-0.75
Percentage change
-1.82
%
IndexRUT P/E33.91 EPS (ttm)1.18 Insider Own4.32% Shs Outstand31.87M Perf Week1.27%
Market Cap1.28B Forward P/E5.94 EPS next Y6.76 Insider Trans-8.80% Shs Float30.58M Perf Month9.83%
Income48.16M PEG61.65 EPS next Q1.48 Inst Own123.86% Short Float22.92% Perf Quarter30.49%
Sales566.77M P/S2.26 EPS this Y12.64% Inst Trans-1.92% Short Ratio15.60 Perf Half Y79.71%
Book/sh6.13 P/B6.55 EPS next Y9.67% ROA4.16% Short Interest7.01M Perf Year66.17%
Cash/sh9.72 P/C4.13 EPS next 5Y0.55% ROE24.68% 52W Range20.83 - 40.91 Perf YTD30.49%
Dividend Est.- P/FCF4.68 EPS past 5Y- ROI7.03% 52W High-1.82% Beta1.03
Dividend TTM- Quick Ratio1.10 Sales past 5Y17.87% Gross Margin57.55% 52W Low92.82% ATR (14)1.16
Dividend Ex-Date- Current Ratio1.17 EPS Y/Y TTM297.95% Oper. Margin30.96% RSI (14)65.42 Volatility2.59% 3.10%
Employees197 Debt/Eq3.45 Sales Y/Y TTM22.17% Profit Margin8.50% Recom1.67 Target Price40.00
Option/ShortYes / Yes LT Debt/Eq2.51 EPS Q/Q482.46% Payout0.00% Rel Volume0.78 Prev Close40.91
Sales Surprise1.27% EPS Surprise14.63% Sales Q/Q15.53% EarningsFeb 22 AMC Avg Volume449.41K Price40.16
SMA204.94% SMA5013.36% SMA20048.11% Trades Volume153,608 Change-1.82%
Date Action Analyst Rating Change Price Target Change
Jan-04-24Downgrade Jefferies Buy → Hold $30 → $37
Aug-25-23Reiterated Needham Buy $35 → $36
May-02-23Resumed Jefferies Buy $30
Aug-08-22Downgrade H.C. Wainwright Buy → Neutral
Feb-15-22Upgrade Cantor Fitzgerald Neutral → Overweight $18 → $26
Aug-06-21Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-11-21Reiterated H.C. Wainwright Buy $29 → $33
Jul-14-20Initiated BWS Financial Sell $8
May-27-20Initiated Guggenheim Neutral
Feb-19-20Resumed Jefferies Buy $43
Mar-18-24 09:40AM
Mar-13-24 12:45PM
Mar-04-24 08:28PM
Mar-01-24 12:00PM
Feb-29-24 09:40AM
11:25PM Loading…
Feb-28-24 11:25PM
Feb-27-24 10:41AM
Feb-23-24 10:20AM
06:09AM
Feb-22-24 07:00PM
05:06PM
04:43PM
04:09PM
04:00AM
Feb-08-24 08:00AM
08:03AM Loading…
Jan-31-24 08:03AM
Jan-24-24 12:10PM
Jan-18-24 07:58PM
Jan-09-24 08:34AM
Jan-04-24 10:40AM
03:17AM
Jan-03-24 08:00AM
Dec-23-23 01:01AM
Dec-21-23 05:01PM
Nov-30-23 07:04AM
Nov-27-23 08:00AM
Nov-14-23 03:08PM
Nov-09-23 08:00AM
Nov-08-23 09:53AM
09:30AM
08:00AM Loading…
08:00AM
Nov-07-23 04:44PM
04:01PM
Nov-01-23 10:01AM
Oct-31-23 10:01AM
Oct-24-23 08:00AM
Oct-12-23 03:47AM
Oct-06-23 09:40AM
Aug-28-23 08:00AM
Aug-24-23 08:00AM
Aug-07-23 07:30AM
Aug-03-23 08:30PM
05:35PM
04:29PM
04:01PM
Jul-28-23 02:56PM
Jul-20-23 08:00AM
Jul-07-23 08:52AM
Jun-22-23 08:30AM
Jun-21-23 08:00PM
Jun-01-23 08:00AM
May-18-23 01:50PM
May-09-23 03:15PM
May-04-23 06:30PM
05:55PM
04:47PM
04:01PM
May-03-23 09:15AM
Apr-27-23 10:03AM
Apr-26-23 08:00PM
Apr-20-23 08:00AM
Apr-11-23 08:00AM
Mar-01-23 11:40AM
07:54AM
Feb-26-23 07:02AM
Feb-24-23 08:52AM
Feb-23-23 05:25PM
04:01PM
Feb-22-23 09:06AM
08:00AM
Feb-21-23 10:00AM
Feb-16-23 10:01AM
Feb-13-23 11:40AM
Feb-07-23 09:54PM
Feb-06-23 04:08PM
04:07PM
Jan-31-23 05:00AM
Jan-30-23 06:35AM
Jan-28-23 07:41AM
Jan-13-23 11:11AM
Jan-11-23 11:40AM
Jan-08-23 12:38PM
Jan-04-23 08:00AM
Dec-22-22 08:00AM
Nov-22-22 08:00AM
Nov-08-22 06:52AM
Nov-03-22 06:15PM
04:01PM
Oct-27-22 10:02AM
Oct-20-22 08:00AM
Sep-30-22 09:27AM
Aug-30-22 08:00AM
Aug-08-22 02:23PM
Aug-04-22 05:35PM
04:01PM
Jul-28-22 10:33AM
10:02AM
Jul-21-22 08:00AM
Jul-06-22 11:19AM
Jun-15-22 10:53AM
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Thomas BEVP and Chief Medical OfficerFeb 29 '24Sale36.7699536,58063,409Mar 04 04:26 PM
Dreyer ScottEVP & Chief Commercial OfficerFeb 26 '24Sale36.4310,000364,270138,918Feb 28 04:14 PM
Dreyer ScottEVP & Chief Commercial OfficerJan 16 '24Sale32.2823,560760,519111,322Jan 18 04:19 PM
Ciaffoni JosephPresident and CEODec 21 '23Option Exercise21.344,35792,978279,357Dec 22 04:36 PM
Ciaffoni JosephPresident and CEODec 21 '23Sale30.384,357132,377275,000Dec 22 04:36 PM
Ciaffoni JosephPresident and CEODec 20 '23Option Exercise21.3426,454564,528301,454Dec 20 05:51 PM
Ciaffoni JosephPresident and CEODec 20 '23Sale30.4026,454804,210275,000Dec 20 05:51 PM
Ciaffoni JosephPresident and CEODec 19 '23Option Exercise21.3414,516309,771289,516Dec 20 05:51 PM
Ciaffoni JosephPresident and CEODec 19 '23Sale30.0314,516435,942275,000Dec 20 05:51 PM
Ciaffoni JosephPresident and CEODec 18 '23Option Exercise21.3427,798593,209302,798Dec 20 05:51 PM
Ciaffoni JosephPresident and CEODec 18 '23Sale30.0427,798834,935275,000Dec 20 05:51 PM
Kuhlmann Shirley R.EVP and General CounselNov 27 '23Option Exercise15.9025,600407,040145,118Nov 29 04:32 PM
Kuhlmann Shirley R.EVP and General CounselNov 27 '23Sale25.7825,600660,014119,518Nov 29 04:32 PM
Kuhlmann Shirley R.EVP and General CounselJun 26 '23Sale21.7217,984390,633119,518Jun 28 04:08 PM
Ciaffoni JosephPresident and CEOJun 02 '23Sale21.6031,272675,424275,000Jun 02 07:08 PM
Ciaffoni JosephPresident and CEOJun 01 '23Sale22.0931,272690,758306,272Jun 02 07:08 PM
Ciaffoni JosephPresident and CEOMay 31 '23Sale21.8731,272683,797337,544Jun 01 04:15 PM
Ciaffoni JosephPresident and CEOMay 30 '23Sale21.9031,271684,907368,816Jun 01 04:15 PM